Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study.

MLA

Qu, Fei, et al. “Efficacy and Safety of RC48-ADC in HER2-Positive and HER2-Low Metastatic Breast Cancer: A Multicenter, Real-World Study.” Frontiers in Oncology, Nov. 2024, pp. 1–11. EBSCOhost, https://doi.org/10.3389/fonc.2024.1435485.

APA

Qu, F., Lu, R., Wu, X., Liu, Q., Zha, M., Li, H., Yuan, Y., Han, Z., Cai, D., Huang, X., Yin, Y., & Li, W. (2024). Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study. Frontiers in Oncology, 1–11. https://doi.org/10.3389/fonc.2024.1435485

Chicago

Qu, Fei, Rongrong Lu, Xinyu Wu, Qian Liu, Mengyao Zha, Huihui Li, Yuan Yuan, et al. 2024. “Efficacy and Safety of RC48-ADC in HER2-Positive and HER2-Low Metastatic Breast Cancer: A Multicenter, Real-World Study.” Frontiers in Oncology, November, 1–11. doi:10.3389/fonc.2024.1435485.